Nanobiotix expects to present the results of its Phase II/III trial in soft tissue sarcoma
in the first half of 2018.
Increasing frequency of soft tissue sarcomas
in The Netherlands.
Furthermore, Halaven was first approved as a treatment for soft tissue sarcoma
in the United States in January 2016, and is approved in countries including Japan and in Europe.
A review of the Soft Tissue Sarcoma
products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Prognostic factors for survival in soft tissue sarcoma
Multidisciplinary management of soft tissue sarcomas
Soft Tissue Sarcoma
Diagnosis Distribution by Sampling Modality Sampling Modality Core Needle Incisional Biopsy Biopsy Tumor Type (n - 103) (n - 107) Synovial sarcoma 18 20 Leiomyosarcoma 10 13 Myxofibrosarcoma 14 20 Fibrosarcoma 4 2 Undifferentiated pleomorphic 33 33 sarcoma Pleomorphic sarcoma 11 5 with myogenic features Myofibrosarcoma 0 1 Sarcoma not otherwise specified 13 8 Myxoinflammatory fibroblastic 0 5 sarcoma Table 3.
Long-term prognosis of primary retroperitoneal soft tissue sarcoma
," Eur J Surg Oncol 2007, Vol.
Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, has announced an update on its PICASSO 3 trial, a randomized, double-blinded, placebo- controlled Phase 3 trial of palifosfamide for the treatment of metastatic soft tissue sarcoma
in the front-line setting.
Ross Houston died of rare soft tissue sarcoma
Cotara is also being studied in a Phase I trial for colorectal, pancreas, soft tissue sarcoma
and biliary cancers at Stanford University.
Soft Tissue Sarcoma
- Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Sant Chawla, the principal investigator of CytRx's global Phase 3 clinical trial for soft tissue sarcoma
M2 PHARMA-October 28, 2016-Philogen announces EC grant of Orphan Drug Designation for treatment of soft tissue sarcoma
The product is intended for the treatment of adults with soft tissue sarcoma
with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.